These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 38999)

  • 1. Antagonism between dopaminergic and neuroleptic drugs. II. Chronic administration.
    Tartara A; Bo P; Savoldi F
    Farmaco Sci; 1979 Jul; 34(7):628-34. PubMed ID: 38999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism between dopaminergic and neuroleptic drugs. I. Acute administration.
    Bo P; Savoldi F; Tartara A
    Farmaco Sci; 1979 Jul; 34(7):621-7. PubMed ID: 38998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration.
    Kulkarni SK; Bishnoi M; Chopra K
    Indian J Exp Biol; 2009 Feb; 47(2):91-7. PubMed ID: 19374163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron modulates neuroleptic-induced effects related to the dopaminergic system.
    Ben-Shachar D; Livne E; Spanier I; Zuk R; Youdim MB
    Isr J Med Sci; 1993 Sep; 29(9):587-92. PubMed ID: 7901181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological studies on timiperone, a new neuroleptic drug Part II: General pharmacological properties.
    Yamasaki T; Kojima H; Tanaka M; Aibara S; Hirohashi M; Kasai Y; Tsubokawa M; Watanabe K; Akashi A
    Arzneimittelforschung; 1981; 31(4):707-15. PubMed ID: 6113834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine-agonist drugs and cerebral electrical activity in the rabbit.
    Savoldi F; Tartara A; Bo P
    Farmaco Sci; 1979 Jun; 34(6):526-34. PubMed ID: 572783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of dopaminergic agonists on genital reflexes in paradoxical sleep-deprived male rats.
    Andersen ML; Tufik S
    Physiol Behav; 2005 Feb; 84(2):205-10. PubMed ID: 15708772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Change in dopamine and serotonin receptor sensitivity following chronic chlorpromazine administration].
    Zharkovskiĭ AM; Riago LK; Arro AG
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1980; 30(1):165-8. PubMed ID: 7189932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haloperidol and apomorphine differentially affect neuropeptidase activity.
    Waters SM; Konkoy CS; Davis TP
    J Pharmacol Exp Ther; 1996 Apr; 277(1):113-20. PubMed ID: 8613907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
    Perry JC; Vital MA; Frussa-Filho R; Tufik S; Palermo-Neto J
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):127-33. PubMed ID: 15013028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in sensitivity of release modulating dopamine autoreceptors after chronic treatment with haloperidol.
    Nowak JZ; Arbilla S; Galzin AM; Langer SZ
    J Pharmacol Exp Ther; 1983 Aug; 226(2):558-64. PubMed ID: 6875865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the mechanism of postetorphine catalepsy. Effects of clotiapine, haloperidol and rompun on postetorphine changes in concentrations of dopamine and noradrenaline in central nervous system of rats.
    Kania BF
    Acta Physiol Pol; 1980; 31(1):9-16. PubMed ID: 6103632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study.
    Haleem DJ; Samad N; Haleem MA
    Behav Pharmacol; 2007 Mar; 18(2):147-53. PubMed ID: 17351421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fuxe K; Werge T; Gerlach J
    Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioural effects of chronic treatment with apomorphine in combination with neuroleptic drugs.
    Kenny M; Leonard BE
    J Neurosci Res; 1980; 5(4):291-8. PubMed ID: 6107385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.